Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation - 12/12/18
Doi : 10.1016/j.ahj.2018.08.010
Islam Y. Elgendy, MD a, ⁎ 
, Hend Mansoor, PharmD, MS b, Qian Li c, Yi Guo, PhD c, Eileen M. Handberg, PhD a, C. Noel Bairey Merz, MD d, Carl J. Pepine, MD a
, Hend Mansoor, PharmD, MS b, Qian Li c, Yi Guo, PhD c, Eileen M. Handberg, PhD a, C. Noel Bairey Merz, MD d, Carl J. Pepine, MD a a Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL
b Department of Health Services Research Management and Policy, University of Florida, Gainesville, FL
c Department of Health Outcomes and Policy, University of Florida, Gainesville, FL
d Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
⁎Reprint requests: Islam Y. Elgendy, MD, Division of Cardiovascular Medicine, Department of Medicine, University of Florida, 1600 SW Archer Rd, PO Box 100288, Gainesville, FL, USA 32610.Division of Cardiovascular Medicine, Department of MedicineUniversity of Florida1600 SW Archer Rd, PO Box 100288GainesvilleFL32610USA
Abstract |
The aim of this study was to determine the long-term prognostic value of the Duke Activity Status Index–estimated metabolic equivalents (METs) values among women with suspected ischemic heart disease. At a median of 9.6 years, the incidence of death was 23.4% in those with METs <4.8 versus 8.2% in METs >9.9, P < .01. In conclusion, use of the simple, patient-reported Duke Activity Status Index could help identify higher-risk women with suspected ischemic heart disease for targeted risk management.
Le texte complet de cet article est disponible en PDF.Plan
© 2018
Elsevier Inc. Tous droits réservés.
Vol 206
P. 123-126 - décembre 2018 Retour au numéro
Article précédent
- The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: A policy primer for clinicians
- Kevin A. Schulman, Matan Dabora
- Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis
- Juhwan Lee, Rine Nakanishi, Dong Li, Kashif Shaikh, Chandana Shekar, Kazuhiro Osawa, Negin Nezarat, Eranthi Jayawardena, Maja Blanco, Matthew Chen, Matthew Sieckert, Eric Nelson, Darius Billingsley, Sajad Hamal, Matthew J. Budoff
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?